Mizuho on Terns Pharmaceuticals (TERN): current MRK deal represents 'excellent outcome' for TERN shareholders
Tweet Send to a Friend
Mizuho analyst Graig Suvannavejh reiterated a Neutral rating and $53.00 price target on Terns Pharmaceuticals (NASDAQ: TERN)The analyst commented, "Yesterday ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
